The content on this site is intended for healthcare professionals only
Prof Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) and Prof Nadia Harbeck (LMU University Hospital, Munich, Germany) discuss the latest breast cancer diagnostics guidelines.
They talk about the updates on the role of the Oncotype DX Breast Recurrence Score and its impact on best practice in care for breast cancer patients.
Prof Harbeck also highlights the latest guideline advice regarding breast cancer and genomics from St Gallen and the upcoming ESMO guidelines.
They further discuss the findings from the ADAPT-TP trial and the monarchE trial and conclude by talking about what the future holds for genetic testing including ctDNA detection and its impact on diagnostics in breast cancer.
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
SABCS 2025: Latest developments in multigene testing in early breast cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Choosing Wisely for young women with breast cancer: Radiotherapy
Hope vs Hype of evidence interpretation
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Choosing Wisely in radiology Tanzania
Why tumour markers are not recommended as screening tests
